Clinical Trial Update: Trastuzumab Deruxtecan Plus Nivolumab Plus Capecitabine Plus Oxaliplatin for HER2 Low Gastric and Gastroesophageal Junction Adenocarcinoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating trastuzumab deruxtecan in combination with nivolumab, capecitabine, and oxaliplatin for HER2-low gastric and gastroesophageal junct…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Adenocarcinoma
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• Eloxatin (oxaliplatin)
• Enhertu (trastuzumab deruxtecan)
• OPDIVO (nivolumab)
• Xeloda (capecitabine)

Snippet

Sponsor: National Cancer Center Hospital East | Conditions: Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | Phase 1, Phase 2 | Status: COMPLETED